MedPointe was founded in 2001 when a group of healthcare executives, backed by two leading private equity firms completed the $408-million acquisition of the Healthcare Business and corporate stock of Carter-Wallace. Carter-Wallace changed its name to MedPointe. MedPointe is a specialty pharmaceutical company that develops, markets and sells branded prescription therapeutics in the areas of allergy, CNS/Neurology/Epilepsy and cough/cold. MedPointe seeks to capitalize on existing opportunities in niche markets through product acquisitions, co-promotion, joint ventures, licensing and other partnership arrangements. MedPointe is actively exploring opportunities to enter other niche markets such as dermatology and women's health.